| |JANUARY 20249CLEARVIEW CANCER INSTITUTE AND ONEONCOLOGY TEAM UP FOR CANCER SERVICES BRAINSEE SOFTWARE RECEIVES FDA APPROVAL FOR WHOLE BRAIN IMAGE ANALYSIS BrainSee (Darmiyan, San Francisco, California) has received De Novo approval from the Food and Drug Administration (FDA) to utilize their first-in-class clinical test for the possible assessment of Alzheimer disease (AD). BrainSee is software that predicts the probability of amnestic mild cognitive impairment (aMCI) developing into Alzheimer's disease (AD) within five years using whole brain image analysis and medical artificial intelligence (AI) technologies. In 2021, the FDA had already designated BrainSee as a breakthrough.BrainSee is a noninvasive software that assesses risk for progression to AD using MRI images and cognitive assessments involved in the standard workup for the clinical assessment of patients who are experiencing memory problems. According to a statement from Darmiyan, the application of BrainSee in clinical practice can potentially enable earlier personalized treatment to delay onset of dementia, as per practicalneurology.Furthermore, the ratings supplied are meant to reduce worry for individuals who are at low risk of developing Alzheimer's disease, avoiding unneeded, costly, and invasive testing."Our vision is to redefine brain health screening and monitoring standards and impact the lives of patients and their family members in a meaningful way. BrainSee is the first product of this vision, backed by our solid technological infrastructure that is capable of driving further transformations and scalable innovations in the brain health landscape," stated Dr. Padideh Kamali-Zare, Founder and CEO of Darmiyan. POTo improve the provision of cancer services to Alabama communities, Clearview Cancer Institute and OneOncology, the nation's fastest-growing platform for independent oncology practices, announced the completion of their agreement.Clearview Cancer Institute is one of the five largest community oncology practices nationally and the largest in Alabama. The practice has 25 medical oncologists caring for patients at 13 cancer care clinics in Huntsville, Decatur, Florence, Oxford, Jasper, Cullman, Scottsboro, and other North Alabama communities, as per pharmabiz.Clearview Cancer Institute has been caring for Alabamians' lives for over 30 years, providing high-quality, customized treatment near to home. The practice provides patients with services across the cancer care continuum, including infusion, oral medication, laboratory, imaging, and clinical research. The practice's medical imaging technology includes MRI, ultrasound, and PET/CT."Partnering with OneOncology will accelerate our growth trajectory across Alabama," said John Waples, MD. "OneOncology's backbone infrastructure, data analytics, and unparalleled expertise assisting growth-oriented practices will unlock opportunities for our physicians and other practices across Alabama to expand patient access to high-quality cancer care at costs far below hospitals, all while maintaining practice independence.""As one of CCI's founders and someone who has practiced in Huntsville since 1979, I've experienced how community oncology has changed and given our patients high-quality cancer care treatment options close to home," said Marshall Schreeder, MD. "In my 30-year career, I've never been as excited for our future as I am now due to our partnership with OneOncology. By affiliating with leading oncology practices and physicians across the country, we will continue to grow and expand access to care throughout North Alabama." PO
< Page 8 | Page 10 >